Total Laparoscopic Hysterectomy With Sacrocolpopexy Versus Total Laparoscopic Hysterectomy With Lateral Suspension in Patients With Pelvic Organ Prolapse

Sponsor
Antalya Training and Research Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03722563
Collaborator
(none)
80
1
2
24.5
3.3

Study Details

Study Description

Brief Summary

This prospective randomized surgical trial is designed to compare objective and subjective outcomes of total laparoscopic hysterectomy with sacrocolpopexy versus total laparoscopic hysterectomy with lateral suspension for the treatment of pelvic organ prolapse

Condition or Disease Intervention/Treatment Phase
  • Procedure: total laparoscopic hysterectomy with sacrocolpopexy
  • Procedure: total laparoscopic hysterectomy with lateral suspension
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Comparison of Total Laparoscopic Hysterectomy With Sacrocolpopexy Versus Total Laparoscopic Hysterectomy With Lateral Suspension in Patients With Pelvic Organ Prolapse: a Randomized Clinical Trial
Actual Study Start Date :
Jan 8, 2019
Actual Primary Completion Date :
Jan 22, 2021
Actual Study Completion Date :
Jan 22, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: TLHS

total laparoscopic hysterectomy with sacrocolpopexy will be performed

Procedure: total laparoscopic hysterectomy with sacrocolpopexy
Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy

Experimental: TLHLS

total laparoscopic hysterectomy with lateral suspension will be performed

Procedure: total laparoscopic hysterectomy with lateral suspension
Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy

Outcome Measures

Primary Outcome Measures

  1. Rate of objective cure [12 months]

    Recurrences of vaginal vault prolapse will be assessed as objective cure by using the pelvic organ prolapse quantification (POP-Q) system

Secondary Outcome Measures

  1. Patient Global Impression of Improvement (PGI-I) [12 months]

    Patient Global Impression of Improvement scale is global index that may be used to rate the response of a condition to a therapy. It is a 7-point scale where a score of 1 indicates that the patient is "very much improved," a score of 4 indicates that the patient has experienced "no change," and a score of 7 indicates that the patient is "very much worse."

  2. International Consultation of Incontinence Questionnaire - Short Form (ICIQ-SF) [12 months]

    The questionnaire contains four items: frequency of urinary incontinence, amount of leakage, overall impact of urinary incontinence and self-diagnostic. The first item has 6 response categories (never, once a week, two or three times a week, once a day, a few times a day, always) and is scored from 0 to 5. The second item has 4 response categories (none, small amount, moderate amount, large amount) and is scored 0, 2, 4, or 6. The third item (how much urine leakage affects your daily life) has 5 response (not at all, mildly, moderately, severely, to a great extent) and is scored from 0 to 10. The first three items are scored and then summed to produce a total score, ranging from 0 to 21. The last item is a diagnostic item to assess the perceived cause of incontinence. This item is included upon the request of clinicians and is not used for scoring. A higher ICIQ-UI-SF score indicates higher frequency, severity, and lower quality of life.

  3. International Consultation on Incontinence Questionnaire on Vaginal Symptoms (ICIQ-VS) [12 months]

    The questionnaire evaluates several pelvic floor dysfunctions including questions regarding intestinal, vaginal, sexual symptoms and quality of life impact. It includes 14 questions (dragging abdominal pain, vaginal soreness, reduced sensation around vagina, vagina too loose/lax, lump coming down in vagina, lump coming out of vagina, dry vagina, digitation for bowel opening, tight vagina, current sex life, worries about vagina affect sex life, relationship, sex life spoilt, overall impact on everyday life) and divided into three independent domains. Vaginal symptoms score varies from 0 to 53. Sexual symptoms score varies from 0 to 58. Quality of life impact score varies from 0 to 10. Usually each question has 3 to 5 possible answers; the higher the score, the most severe is the symptom or the negative quality of life impact.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women with symptomatic pelvic organ prolapse stage II or higher (according to the International Continence Society Pelvic Organ Prolapse quantification system - POPQ) in anterior and/or apical (central) compartment that require surgical management
Exclusion Criteria:
  • Patients that are not candidates for general anesthesia or laparoscopy

  • Inability to consent

  • history of hysterectomy

  • history of anterior or apical pelvic organ prolapse surgery

  • history of urinary incontinence surgery

  • pregnancy or breast-feeding during the study period

  • suspicious adnexal masses or other factors that may indicate pelvic malignancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Antalya Training and Research Hospital Antalya Muratpaşa Turkey 07230

Sponsors and Collaborators

  • Antalya Training and Research Hospital

Investigators

  • Principal Investigator: Bekir Sıtkı İsenlik, MD, Antalya Training and Research Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
bekirsitkiisenlik, principal investigator, Antalya Training and Research Hospital
ClinicalTrials.gov Identifier:
NCT03722563
Other Study ID Numbers:
  • TLHSvsTLHLS
First Posted:
Oct 29, 2018
Last Update Posted:
Feb 12, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by bekirsitkiisenlik, principal investigator, Antalya Training and Research Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 12, 2021